Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.

导出 OA

翻译打印收藏纠错

作者： Guus J J E,Heynen ^[1] ; Kamil,Lisek ^[2] ; Regina,Vogel ^[2] ; Annika,Wulf-Goldenberg ^[3] ; Joshua,Alcaniz ^[3] ; Elodie,Montaudon ^[4] ; Elisabetta,Marangoni ^[4] ; Walter,Birchmeier ^[2]

作者单位： Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Society, Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125, Berlin, Germany. gustaaf.heynen@mdc-berlin.de. ^[1] Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Society, Campus Berlin-Buch, Robert-Rössle-Str. 10, 13125, Berlin, Germany. ^[2] Experimental and Pharmacological Oncology (EPO), Campus Berlin-Buch, Building 82, Robert-Rössle-Str. 10, 13125, Berlin, Germany. ^[3] Preclinical Investigation Laboratory, Institut Curie, 20 Rue d'Ulm, 75248, Paris, France. ^[4]

关键词 Breast cancer Drug resistance PI3K and MAPK signaling SHP2 Targeted therapy

主题词乳腺肿瘤(Breast Neoplasms);女(雌)性(Female);人类(Humans);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);蛋白质酪氨酸磷酸酶, 非受体11型(Protein Tyrosine Phosphatase, Non-Receptor Type 11);信号传导(Signal Transduction)

DOI 10.1186/s13058-022-01521-3

PMID 35365185

发布时间 2022-06-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交